Physician profile
Joel E Bruce
NPI 1154387199
$3,660.64
in general payments reported to CMS, 2019-2025
22 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $37.60 · 2021: $75.17 · 2022: $147 · 2023: $938 · 2024: $964 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Education: $81.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.38 |
| Education | $81.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $705.88 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Akebia Therapeutics INC | $322.27 | 2021-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals Lp | $309.51 | 2023-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $294.30 | 2024-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $278.88 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $221.26 | 2023-2025 | |
| Vifor Pharma, INC. | $209.66 | 2020-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $191.23 | 2024-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $174.73 | 2023-2025 | |
| Outset Medical INC | $171.13 | 2023 | |
| Novartis Pharmaceuticals Corporation | $148.33 | 2025 | |
| Nxstage Medical, INC. | $144.04 | 2022-2023 | Nxstage System One |
| Calliditas Therapeutics US INC. | $136.25 | 2025 | Tarpeyo |
| Baxter Healthcare | $132.15 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.95 | 2023-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $29.57 | 2023 | Ibsrela |
| Horizon Therapeutics Plc | $24.97 | 2023 | Krystexxa |
| Exact Sciences Corporation | $19.96 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $18.25 | 2025 | Tryvio |
| Mallinckrodt Enterprises LLC | $17.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $16.62 | 2020 | |
| Fresenius USA Marketing, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.